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Abstract
Introduction Pain is a common non-motor symptom in Parkinson’s disease (PD), affecting up to 85% of patients. The fre-
quency and stability of pain over time has not been extensively studied. There is a paucity of high-quality studies investigating 
pain management in PD. To develop interventions, an understanding of how pain changes over the disease course is required.
Methods One hundred and fifty-four participants with early PD and 99 age-and-sex-matched controls were recruited as part 
of a longitudinal study (Incidence of Cognitive Impairment in Cohorts with Longitudinal Evaluation in PD, ICICLE-PD). 
Pain data were collected at 18-month intervals over 72 months in both groups using the Nonmotor Symptom Questionnaire 
(NMSQ), consisting of a binary yes/no response. Two questions from the Parkinson’s Disease Questionnaire (PDQ-39) were 
analysed for the PD group only.
Results Unexplained pain was common in the PD group and occurred more frequently than in age-matched controls. ‘Aches 
and pains’ occurred more frequently than ‘cramps and muscle spasms’ at each time point (p < 0.001) except 54 months.
Conclusions This study shows that pain is prevalent even in the early stages of PD, yet the frequency and type of pain fluctu-
ates as symptoms progress. People with PD should be asked about their pain at clinical consultations and given support with 
describing pain given the different ways this can present.
Keywords Parkinson’s disease · Pain · Longitudinal
Introduction
Pain is a common, under recognised symptom in people with 
Parkinson’s disease (PD) [1] with up to 85% of people with 
PD reporting pain [2, 3]. Pain influences quality of life and 
is ranked by people with PD as one of the most troublesome 
early non-motor symptoms [7]. There have been a number 
of cross-sectional studies evidencing a significantly higher 
prevalence of pain in people with PD compared to age-
matched controls [4–6]. Currently, the largest study of pain 
(n = 1957) [2], a cross-sectional study, focused on a sample 
of early stage PD, but to date there have been few longitudi-
nal studies of early PD or with matched controls to explore 
changes of pain over time. To date, management options 
are limited, and there is a need for high-quality studies to 
enhance our understanding to direct therapies to manage 
pain in PD [8].
To date, no longitudinal studies have focused primarily 
on pain in PD; however, some measured pain as a small 
component alongside other non-motor symptoms [10–13] 
or quality of life [14, 15]. Three studies followed individu-
als over 2 years and found the presence of pain to be one of 
the most common symptoms at baseline [10], which could 
remain relatively stable [13] to significantly worsen with 
those in the early stages of PD (< 2 years), irrespective of 
dopaminergic therapy [11]. Within these studies only one 
measure of pain was collected. Three studies performed a 
4-year follow-up and found the presence [15] and frequency 
of pain to significantly increase [12] and that the increase of 
pain has a direct impact on cost on disease expenditure over 
time [14]. However, the stability of pain over time in people 
with PD was not explored, and pain formed a very limited 
focus of each of the studies. One study [10] had a control 
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group, but did not measure unexplained pain. Unexplained 
pain has been highlighted as a problem in PD [16] and war-
rants further investigation over time to understand how pain 
evolves. We hypothesised that pain in PD would be more 
prevalent than age-matched controls over time and that the 
frequency of pain in PD would increase.
Methods
The study was approved by the Newcastle and North 
Tyneside 1 Research Ethics Committee and performed 
according to the Declaration of Helsinki. All participants 
provided written informed consent. Recently, diagnosed peo-
ple with PD were recruited from the community and outpa-
tient clinics in Newcastle upon Tyne and Gateshead from 
June 1, 2009 to December 31, 2011 as part of the Incidence 
of Cognitive Impairment in Cohorts with Longitudinal Eval-
uation in PD (ICICLE-PD) study [17]. Full inclusion criteria 
have been detailed elsewhere [17]; in brief, newly diagnosed 
people with PD diagnosed by a movement disorders expert 
according to the UK Brain Bank criteria were included. Par-
ticipants returned at 18-month intervals for follow-up evalu-
ation. Age- and sex-matched healthy control subjects were 
recruited from the local community and underwent a similar 
assessment schedule as PD participants.
Assessments
At each assessment, demographic and clinical data were col-
lected including disease severity measured by the Hoehn 
& Yahr (H&Y) scale, Movement Disorders Society Unified 
Parkinson’s Disease Rating Scale (MDS-UPDRS) [18] Part 
III, Geriatric Depression Scale (GDS-15) [19] and levodopa 
equivalent daily dose (LEDD). Global cognitive function 
was assessed using the Mini-Mental State Examination 
(MMSE) [20] and Montreal Cognitive Assessment (MoCA) 
[21].
Self-reported pain was recorded at 18-month intervals 
over 72 months using the Nonmotor Symptom Questionnaire 
(NMSQ) [22], consisting of a binary yes/no response for 
both the PD and control group. In PD participants, the Par-
kinson’s Disease Questionnaire (PDQ-39) [23] bodily dis-
comfort domain was analysed as well as two individual items 
from this domain; ‘had painful muscle cramps or spasms?’ 
and ‘had aches and pains in your joints or body?’
Statistical analysis
Statistical analysis was performed using IBM SPSS software 
(version 22). Demographic characteristics were compared 
between groups using independent t tests, Mann–Whitney U 
tests, and Chi-square statistics, as appropriate. Comparison 
of the NMSQ for the PD and control group at the five time 
points was assessed using Chi-squared tests. Repeated-meas-
ures testing of categorical variables over time was assessed 
with Cochran’s Q, with post hoc McNemar test, with a Bon-
ferroni adjustment applied to correct for multiple testing. 
The means from clinical assessments at each time point for 
the PD group were compared using analyses of variance or 
Kruskal–Wallis tests, with post hoc Dunn’s test as appropri-
ate. We split these clinical assessments into the presence of 
unexplained pain from the NMSQ and frequency of painful 
cramps and muscle spasms and aches and pains from the 
PDQ-39. The PDQ-39 bodily discomfort domain and the 
two selected items were compared separately over each time 
point using Friedman test with a post hoc Wilcoxon signed-
rank test and a Bonferroni adjustment applied to correct for 
multiple testing. The frequency of painful cramps and mus-
cle spasms and aches and pains were compared at each time 
point using the Wilcoxon signed-rank test and a Bonferroni 
adjustment applied to correct for multiple testing. Stability 
of pain over time for unexplained pain, painful cramps, and 
muscle spasms and aches and pains were calculated descrip-
tively using frequencies.
Results
One hundred and fifty-four newly diagnosed participants 
with PD and 99 age-matched controls completed baseline 
assessments and the NMSQ. Figure 1 presents a flowchart 
of the number of individuals at each time point. Baseline 
comparisons of both groups are presented in Table 1. PD 
participants scored significantly lower for global cognition 
and significantly higher for depression. No other significant 
differences between the groups were found (p > 0.05 for all).
Unexplained pain (NMSQ)
The PD group reported more unexplained pain than the 
control group, with this being statistically significant at 
each time point except 36 months (baseline: 3% vs. 38%, 
respectively, p < 0.001; 18 mo: 2% vs. 45%, respectively, 
p < 0.0001 36 mo 17% vs. 29%, respectively p = 0.057; 
54 mo 16% vs. 36%, respectively, p = 0.005; 72 mo 5% vs. 
33%, respectively, p < 0.001).
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Stability of pain over time in PD: unexplained pain
Cochran’s Q test did not indicate any significant differ-
ence across the five time points (62% vs. 55% vs. 71% 
vs. 64% vs. 67%, respectively, p = 0.76) for the NMSQ 
for the PD group. 18–36 months demonstrated the largest 
percentage change with participants moving from pain to 
no pain (61% of the pain group). Unexplained pain fluctu-
ated among the group. Of the overall sample, 2% had pain 
consistently at each time point, 9% consistently had no 
pain over time, and the remaining 38% fluctuated between 
yes and no up to 72 months. Between 29 and 45% of the 
sample experienced unexplained pain at each time point. 
Figure 2 presents the stability of unexplained pain over 
time from NMSQ in the PD group.
Table 2 reports the clinical characteristics of those with 
and without unexplained pain. At 18 months (p = 0.006) 
and 36 months (p < 0.001), participants were significantly 
younger who reported pain. Females were significantly 
more likely to experience unexplained pain than males 
at baseline (p = 0.029), 36 (p = 0.040), and 54 months 
(p = 0.001). MDS-UPDRS III scores, Hoehn and Yahr 
stage or LEDD were not significantly different at any time 
point (p > 0.05 for all) between the presence and absence 
of unexplained pain.
Fig. 1  Flow diagram of partici-
pants
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PDQ‑39 bodily discomfort
One hundred and fifty-three of the 154 newly diagnosed 
individuals with PD completed the PDQ-39 at baseline. 
Table 3 presents the number completed at each time point. 
The frequency of bodily discomfort increased over time 
(p < 0.001), and the frequency of participants reporting 
‘muscle cramps or spasms’ (Q37) increased over time 
(p ≤ 0.005); however, ‘aches and pains’ in your joints or 
body? (Q38) demonstrated no significant change over time 
(Bonferroni correction p > 0.005). The item scores of pain-
ful muscle spasms and aches and pains were compared at 
each time point, demonstrating that aches and pains were 
more frequent pain at all time points (p < 0.01 for all) 
except 54 months (p > 0.05). No participant consistently 
reported ‘never’ for experiencing aches and pains (Sup-
plementary materials). Instead, these symptoms fluctuated, 
with the largest percentage increase in frequency between 
baseline and 18 months (9%). The frequency of painful 
muscle cramps and spasms increased over time (Supple-
mentary materials) with only 2% of individuals having 
never experienced muscle spasms and cramps over time.
Table 3 presents the demographic and clinical character-
istics of PD participants at each time point for the individual 
pain items (Q37 and Q38) of the PDQ-39. Those who had 
a higher frequency of muscle cramps and spasms at each 
time point were younger, except 18 months. There were no 
significant differences between the frequency of muscle 
cramps and spasms and MDS-UPDRS lll at any time point 
except baseline. There was a significant difference between 
never experiencing aches and pains to often to always expe-
riencing these between 0 and 18 and 18–36 months for the 
MDS-UPDRS lll score. There was no significant difference 
between the painful muscle cramps and spasms groups 
according to H&Y stage. The H&Y stage was significantly 
higher as pain frequency increased between the aches and 
pains group for baseline (p = 0.005). There was no sig-
nificant difference between LEDD and frequency of either 
muscle cramps and spasms or aches and pains. Depression 
(GDS-15) at baseline, 18 and 36 months demonstrated a sig-
nificant difference, with higher scores for the often-always 
groups of both.
Discussion
We have shown that unexplained pain is common across the 
early stages of PD and occurs more frequently than in age-
matched controls. To our knowledge, this is the first study 
to explore the presence, frequency, and trajectory of pain in 
PD over 72 months.
Whilst it is known from cross-sectional studies that pain 
often occurs more frequently in people with PD than age-
matched control group [4], few longitudinal studies that 
capture pain have included a comparator. One longitudinal 
study exploring non-motor symptoms over 2 years reported 
that the severity of ‘pain and other sensations,’ measured by 
a single item on the MDS-UPDRS, was significantly more 
severe in the PD compared to age-matched controls [10]. 
The current study enhances our understanding of the pres-
ence of unexplained pain specifically being significantly 
higher in the PD group over time, as well as consideration 
of a longer time period. This is an important finding, as it 
has been identified that people with PD are uncertain about 
raising the problem of unexplained pain to healthcare pro-
fessionals due to uncertainty regarding the link to PD and 
uncertainty surrounding treatment despite facing daily chal-
lenges with this symptom [24].
Our study identified that between 29 and 45% of people 
with PD reported unexplained pain at each assessment. This 
finding is in agreement with a longitudinal study explor-
ing the progression of non-motor symptoms over 2 years, 
Table 1  Baseline characteristics of the PD group and age-matched 
control group
Bold indicates a significant difference
a χ2
b Independent t test
c Mann–Whitney U test
d 97/99 control group completed and 140/154 PD group completed
PD (n = 154) Controls (n = 99) p value
Gender, male, n (%) 99 (64.3) 54 (54.5) 0.122a
Age, years mean (SD) 67 (10.4) 68 (8.1) 0.270b
MDS-UPDRS part lll 
sub score, mean (SD)
27 (12.1) n/a n/a
Hoehn & Yahr stage, n (%)
 1 35 (22.7) n/a n/a
 2 88 (57.1) n/a n/a
 3 30 (19.5) n/a n/a
 4 1 (0.6) n/a n/a
 5 0 n/a n/a
LEDD (mg/day) 178.0 (148.2) n/a n/a
MMSE, mean (SD) 28.6 (1.3) 29 (1.2) 0.006c
MoCAd mean (SD) 25 (3.6) 27 (2.5) 0.001c
GDS-15, mean (SD) 2.8 (2.5) 1.0 (1.5) 0.001c
Pain diagnoses n (%)
 Low back pain 5 (3) 4 (4) 0.739a
 Osteoarthritis 22 (14) 17 (17) 0.535a
 Inflammatory arthritis 4 (2) 1 (1) 0.376a
 Other MSK condition 16 (10) 16 (16) 0.178a
 Osteoporosis 8 (5) 3 (3) 0.410a
 Joint replacement 10 (6) 13 (13) 0.073a
 Adult fracture 8 (5) 5 (5) 0.960a
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in which unexplained pain was approximately 40% at each 
time point [13]. Our findings highlight the presence of unex-
plained pain fluctuates among individuals over a longer time 
frame and develops our understanding of the trajectory of 
this type of pain with only 2% of individuals consistently 
reporting this symptom at each time point. Thus, this symp-
tom may be reported for the first time or change at various 
stages during the course of PD, highlighting the importance 
of screening for unexplained pain at routine clinical consul-
tations [24]. A previous cross-sectional study highlighted 
the role of central processes in pain within early/moder-
ate PD [2] and encouraged moving away from a focus on 
peripheral processes. Pain has been highlighted as one of 
the most bothersome non-motor symptoms in early PD [7] 
and, this study highlights that unexplained pain symptoms 
are common even in early PD. Of note, the NMSQ captured 
unexplained pain. Chronic pain is known to recur and should 
not be seen as discrete events [25]. The time of reporting 
may also influence the responses, and may be prone to recall 
bias, with the response only applying to the specific time 
the measure was taken. A yes/no response does not capture 
the individual’s history of pain, the severity or frequency of 
the pain, and their longer term trajectory [25]. Prognostic 
factors for pain, such as pain intensity and beliefs that pain 
will last into the future, have been associated with poor out-
come in low back pain [26], but such associations have not 
been explored in PD. Future studies should aim to capture 
a wider range of factors to understand pain reporting in PD, 
and prognostic factors.
The presence or absence of unexplained pain was not 
associated with motor severity (MDS-UPDRS III), dis-
ease stage (H&Y), or LEDD, corroborating findings from a 
shorter longitudinal study [12]. Currently, the link between 
pain and motor symptoms is unclear [27] and exploration 
of the different descriptions of pain as captured within our 
study can develop understanding of reporting of symptoms 
at different time points.
The PDQ-39 bodily discomfort domain was used in the 
current study to determine self-reported frequency of pain. 
The different descriptions of pain through two of these ques-
tions allowed detailed exploration of their relationship with 
other symptoms. An increased frequency of aches and pains 
Fig. 2  Changes in unexplained pain from baseline to 72 months
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was associated with an increased MDS-UPDRS lll score up 
to 36 months, whereas ‘occasional to sometimes’ muscle 
spasms or cramps was associated with higher MDS-UPDRS 
lll scores at baseline and 54 months, but not ‘always to fre-
quent’ symptoms. The reporting of aches and pains remained 
fairly consistent across the different time points, albeit with 
fluctuations among individual participants. However, report-
ing of painful muscle cramps and spasms changed; although 
45% never experienced this at baseline, only 2% never expe-
rienced this over 6 years. The highest percentage (28%) of 
individuals experiencing muscle cramps and spasms ‘often 
to always’ was observed at the final time point; 72 months. 
How individuals describe their pain is relevant to consider 
during clinical consultations. Individuals may experience 
different types of pain at different times, and these may not 
be mutually exclusive [30]. During pain assessments, the 
different descriptions and types of pain need to be captured 
[27] as demonstrated in the present study.
Up to 36 months, there was a trend for individuals expe-
riencing unexplained pain and increased frequency of aches 
and pains or muscle spasms and cramp to be younger. This 
finding is in agreement with current cross-sectional studies, 
highlighting individuals with pain are often of a younger 
age, and younger age at onset being linked with pain in PD 
[2, 27, 28]. Geriatric depression score followed a trend to 
be higher in the more frequent pain groups of the PDQ-39 
at each time point, with this finding echoing current cross-
sectional studies exploring the association between depres-
sion, pain and PD [2, 28].
Longitudinal studies often report only one measure of 
pain [10, 11, 13]. Erro et al. explored the same measures as 
in the present study, which focused on non-motor symptoms 
and quality of life over a 4-year period [12]. The bodily dis-
comfort domain of the PDQ-39 worsened over time, indicat-
ing an increased frequency of this symptom. However, this 
longitudinal study [12] provided very limited detail regard-
ing pain. The present study has provided detail of how pain 
is described over time by people with PD and developed 
understanding of the trajectory. A number of cross-sectional 
studies classify the type of pain experienced by people with 
PD, with musculoskeletal pain highlighted as the most 
frequent [28, 29] and documenting the different types of 
pain reported by people with PD [30]. Further research is 
required longitudinally using measures such as the Kings 
Parkinson’s Pain Scale [31], which capture the type of pain 
people with PD experience in more greater detail using con-
sistent measuring tools and classifications to allow compari-
sons across the literature.
The key strength of this study is that a large cohort 
of patients with newly diagnosed PD and age-matched 
controls were recruited and followed longitudinally over 
6 years. Other strengths include the use of validated instru-
ments for the assessment of motor symptoms and NMSQ 
and the measures of pain being validated in a PD group. 
This study does have several limitations. A number of par-
ticipants did not return for further assessments; these par-
ticipants may have been important to the findings of this 
study. It is possible that these patients may have reported 
a higher burden of pain. However, on exploration of drop 
out from each of the pain groups, the trend remained the 
same over time for each of the pain questions (data not 
shown). We did not use a specific measure of pain within 
this study or explore the use of pain medication, which 
should be investigated in future studies.
In conclusion, pain in PD is prevalent in the early stages 
of the disease, and the type and frequency of pain people 
with PD experience fluctuates. People with PD should be 
asked about their pain at each clinical consultation and 
given support with describing this given the different ways 
this can present.
Supplementary Information The online version contains supplemen-
tary material available at https:// doi. org/ 10. 1007/ s00415- 021- 10586-7.
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